OBJECTIVES:
- To detect antibodies against NF155, nodal neurofascins (NF140, NF186) and CNTN1 in Amyotrophic neuralgia patients from Switzerland (ICQ).
SAMPLES:
- For CNTN1: 21-2-0106, 21-2-0107, 21-2-0108, 21-2-0114, positive and negative control.
- For NF140-186: 21-2-0106, 21-2-0107, 21-2-0108, 21-2-0114, positive and negative control.
- For NF155: 21-2-0106, 21-2-0107, 21-2-0108, 21-2-0114, positive and negative control.
ICC CNTN1:
Blocking solution: Rabbit serum in PBS.
- Patient’s sera diluted 1/100 in rabbit sèrum in PBS.
- Primary antibody: anti-CNTN1 diluted 1/1000.
- Secondary antibodies: RAG 488 + RAH 594 (1/1000)
- Vectashield mounting medium.
ICC NF155/NF140/NF186:
Blocking solution: 5% goat serum in PBS.
- Patient’s sera diluted 1/100 in 5% goat serum in PBS.
- Primary antibody: anti-NF diluted 1/1000.
- Secondary antibodies: GAC488 + GAH 594 (1/1000).
- Vectashield mounting medium
RESULTS: All samples were negative. However, we couldn’t see the targetting of the CNTN1 with the primary antibody in all samples, including the positive control (it wasn’t due to the transfection because we saw the targetting in red).
